<?xml version="1.0" encoding="UTF-8"?>
<p>For African children with uncomplicated malaria, the World Health Organization (WHO) recommends prompt treatment with artemisinin-based combination therapies (ACTs) within 24 hours of illness onset as a key strategy for preventing progression to severe malaria [
 <xref rid="pone.0217262.ref001" ref-type="bibr">1</xref>]. Unlike in the past, when ACTs were scarce and expensive [
 <xref rid="pone.0217262.ref002" ref-type="bibr">2</xref>], efforts by governments, international organizations, and partner institutions have resulted in increased availability of high quality and affordable ACTs in both the private and public health sectors [
 <xref rid="pone.0217262.ref003" ref-type="bibr">3</xref>]. This achievement has likely contributed greatly to reductions in malaria morbidity and mortality in Africa [
 <xref rid="pone.0217262.ref004" ref-type="bibr">4</xref>, 
 <xref rid="pone.0217262.ref005" ref-type="bibr">5</xref>]. However, despite increases in ACT coverage rates, the proportion of eligible children receiving ACTs within 24 hours of illness onset remains low [
 <xref rid="pone.0217262.ref006" ref-type="bibr">6</xref>], partly explaining why hundreds of thousands of children continue to die of malaria each year [
 <xref rid="pone.0217262.ref007" ref-type="bibr">7</xref>].
</p>
